UK Community Advisory Board (UK-CAB)
Email | |
Janssen pre-meeting
Janssen company meeting
UK-CAB internal meeting
Meeting report – confidential, available to members only
Meeting slides – confidential, not for publication
Janseen have an HIV vaccine in phase 3 studies, including MOSAICO. They funded these studies as a private company – very unusual.
The company also has a vaccine against COVID-19 that only needs a single vaccination and that still works against the South African B.1.351 variant.
Both vaccines use the similar approaches, using the inactivated Ad26 adenovirus to deliver the vaccines.
Some concerns over the Oxford/AstraZenica vaccine and risk of rare blot clots have suggested that it might be linked to the adenovirus as a class – which Janssen have denied.
On 23 April 2021 the FDA undated information to include this as a risk:
Info about authorisation of Janssen COVID-19 vaccine in the US
Proposal to contribute vaccines to low income countries
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.
This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.
